CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 17 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-11-23 | Graham G. Walmsley Director | Conversion · Series B Convertible Preferred Stock | −1,400,761 | 0 | ||
| 2020-11-23 | Graham G. Walmsley Director | Conversion · Series C Convertible Preferred Stock | −1,183,114 | 0 | ||
| 2020-11-23 | RAPPAPORT ANDREW Director | Conversion | +318,723 | 351,181 | ||
| 2020-11-23 | RAPPAPORT ANDREW Director | Conversion | +129,833 | 481,014 | ||
| 2020-11-23 | RAPPAPORT ANDREW Director | Conversion · Series A Convertible Preferred Stock | −318,723 | 0 | ||
| 2020-11-23 | RAPPAPORT ANDREW Director | Conversion · Series A-1 Convertible Preferred Stock | −129,833 | 0 | ||
| 2020-11-23 | Myles David C. Chief Development Officer | Conversion | +12,831 | 12,831 | ||
| 2020-11-23 | Myles David C. Chief Development Officer | Conversion | +154,846 | 154,846 | ||
| 2020-11-23 | Myles David C. Chief Development Officer | Conversion · Series A Convertible Preferred Stock | −12,831 | 0 | ||
| 2020-11-23 | Myles David C. Chief Development Officer | Conversion · Series A Convertible Preferred Stock | −154,846 | 0 | ||
| 2020-11-23 | MCCORMICK FRANK Director | Conversion | +152,891 | 191,113 | ||
| 2020-11-23 | MCCORMICK FRANK Director | Conversion | +66,326 | 84,260 | ||
| 2020-11-23 | MCCORMICK FRANK Director | Conversion · Series A-1 Convertible Preferred Stock | −152,891 | 0 | ||
| 2020-11-23 | MCCORMICK FRANK Director | Conversion · Series A Convertible Preferred Stock | −66,326 | 0 | ||
| 2020-11-23 | Kushner Peter J. Chief Scientific Officer | Conversion | +228,761 | 1,301,513 | ||
| 2020-11-23 | Kushner Peter J. Chief Scientific Officer | Conversion | +130,159 | 1,431,672 | ||
| 2020-11-23 | Kushner Peter J. Chief Scientific Officer | Conversion · Series A Convertible Preferred Stock | −228,761 | 0 | ||
| 2020-11-23 | Kushner Peter J. Chief Scientific Officer | Conversion · Series A-1 Convertible Preferred Stock | −130,159 | 0 | ||
| 2020-11-23 | Harmon Cyrus Chief Technology Officer | Conversion | +71,374 | 1,111,546 | ||
| 2020-11-23 | Harmon Cyrus Chief Technology Officer | Conversion | +122,028 | 122,028 |
Page 20 of 21 · 402 trades